

Humber Area Prescribing Committee

Date / Time	5 th June 2024 13:00-15:00
Venue	MS Teams
Chair	Dr Sergio Raise
Notes / Action Points	Luke Storr – Senior Pharmacy Technician, HUTH
Quorate: Yes / No	No – JM to confirm with SP outside of meeting.

Attendance	Dr Sergio Raise, ERY CCG GP Prescribing Lead (SR) Jane Morgan, Principal Pharmacist - Formulary, Interface and Medicines Commissioning, HUTH (JM) Luke Storr – Senior Pharmacy Technician, HUTH (LS) Andrew Karvot – Advanced Clinical and Northern Lincolnshire Interface Pharmacist, NLAG (AK) Laura Bulmer, Pharmacy Technician Project Manager, NECS (LB) Kevin McCorry, Medicines Optimisation Pharmacist, NECS (KMc) Daniel Newsome- Principal Pharmacist RDTCC (DN) Caroline Hayward- Professional Development Pharmacist, Humber Local Pharmaceutical Committee (CH) Joanne Goode – Chief Pharmacist – HUTH (JG) Dr Rolan Schreiber, Medical Secretary LMC (RSc) Laura Angus- Chief Pharmacy Officer/ Director of Pharmacy and Medicines Optimisation- NHS Humber and North Yorkshire ICB (LA) Prof A Morice, Professor of Respiratory Medicine HUTH- (AM) Catherine Smith- Senior Medicines Optimisation Pharmacist, NECS Narayana Pothina- Consultant in adult medicine, NLAG (NP) Manjeet Kaur-Deputy Chief Pharmacist, Rotherham, Doncaster and South Humber Foundation Trust (MK) Weeliat Chong, Chief Pharmacist, Humber Teaching NHS Foundation Trust (WC) Marian Opoku-Fofie – Deputy Chief Pharmacist – Humber Teaching NHS Foundation Trust (MOF) Emma Baggaley, Assistant Director Medicines Management (Superintendent Pharmacist), CHCP (EB)
-------------------	--

Apologies

Simon Priestley- Chief Pharmacist, NLAG (SP)

Natasha Suffill- Lead Clinical Pharmacist CHCP (NS)

Agenda Number	Item	Discussion	Action	Lead	Due Date
2024.06.01	Apologies	Noted above			
2024.06.02	Declarations of interest	None			
2024.06.03	Minutes of previous meeting	Accepted as true record			
2024.06.04	Action Tracker	<p>Outstanding actions from NLAPC</p> <p>Funding for SCFs – mycophenolate, modafinil and riluzole (joint SCFs)</p> <p>JM to provide RS information on number of patients in NEL/NL</p> <p>December update: JM provided RS with patient numbers for mycophenolate, modafinil and riluzole</p> <p>February update: RS confirmed SCFs for modafinil and riluzole available within NEL; JM to upload SCFs (riluzole and modafinil for NEL).</p> <p>March update: SCFs uploaded onto Humber APC and linked into formulary. Awaiting NL – RS to update</p> <p>April update: Riluzole to JM to update websites to include NL</p> <p>May update: Riluzole updated, modafinil still waiting for NL, mycophenolate to review</p> <p>June update: Modafanil still waiting on NL, JM to review mycophenolate for July guideline group</p> <p>July update: JM to correct typo and send to RS, JM to review mycophenolate SCF for neurology for September guideline group</p> <p>August update: JM corrected typos, changed over on web and sent to RS, JM still to review mycophenolate SCF for September guideline group</p> <p>September 2023 update: For September guideline group</p> <p>October 2023 update: For November Guideline group</p>	Ongoing	JM	7/24

		<p>September update: HUTH audits still ongoing October update: HUTH audits still ongoing November update: HUTH audits still ongoing December 2023 update: HUTH audits still ongoing, infliximab need more data and started adalimumab audit for homecare patients as recently done brand/provider switch. February 2024 update: Ustekinumab audit outcome form presented which demonstrated compliance with NICE guidance. March 2024 update: Infliximab paper due to presented at April D&TC April 2024 update: HUTH D&TC not until next week to update next time May 2024 update: Infliximab paper presented to HUTH D&TC at last meeting alongside updated guidance (on agenda). HUTH infliximab IBD audit was presented to D&TC and noted multiple dosage regimens are in use. Evaluated cost effectiveness versus current second line agents (vedolizumab or ustekinumab) and escalated infliximab is significantly more cost effective. This will be reviewed as more biosimilar agents become available.</p> <p>Outstanding actions from HERPC: Rheumatology to prepare pathway with rituximab without MTX</p> <p>August update: received NLAG pathway which includes this but not received HUTH pathway. Shared NLAG pathway with Dr Ogumbambi (rheumatology lead in HUTH). Rheumatology pathway for HUTH on D&TC action tracker. To discuss at September D&TC if Dr Ogumbambi in attendance and to contact to confirm place in pathway, to enable JM to start writing paper.</p> <p>September update: September D&TC next week, further updates to pathway needed October update: Awaiting updated pathway November update: Pathway needs further updates as new TAs published again and pharmacist who is updating has prioritised adalimumab switch. December update: ongoing February 2024 update: JG to follow up with Dr Ogumbambi March 2024 update: JG raised at HUTH D&TC; to bring NLAG RA pathway to next guideline group and invite Dr Alvi. April 2024 update: NLAG RA pathway on agenda</p>	Ongoing	JM	6/24
--	--	---	---------	----	------

		<p>May 2024 update: HUTH RA pathway currently circulating rheumatologists for comment. June 2024 update: ongoing Ratification of guidelines and SCFs: Sick Day Guidance in T2DM JM to discuss with Matthew Heppel about printing this in colour/black and white and discuss with comms team December 2023 – ongoing February 2024 – ongoing April 2024 – ongoing May 2024 – reviewed wording of document to simplify and transferred into black and white. To add to agenda next month June 2024 – on agenda Ratification of guidelines and SCFs: Amiodarone SCF JM to do minor updates and feedback to cardiology team at HUTH; check patient number for NEL/NL from NLAG/HUTH September 2023 update: JM fed back to cardiology team and updated. JM/AK to confirm patient numbers being dispensed at NLAG sites. October 2023 – RS fed back comments from NEL/NL GP leads. JM sent comments to cardiology team. JM confirmed patient numbers from outsourced outpatients at NLAG. November 2023 – to be discussed at next cardiology governance December 2023 - received comments from cardiology JM to review and send to RS/Catherine Smith after review February 2024 update: ongoing March 2024 update: JM to send updated SCF to CS for review. April 2024 update: ongoing May 2024: reviewed and needs reviewing against RDTC documentation. Either back to guideline/SCF group or to APC dependant on number of changes. Feedback from Integrated Medicines Optimisation Committee - Sodium valproate prevent compliance December 2023 –RS sent JM audit report and JM fed back to neurologists who state all their patients have annual review and forms. March 2024 update – ICB meetings with stakeholders underway. JM updating HUTH internal policy which will be shared with NLAG.</p>	<p>On agenda (completed here)</p> <p>Ongoing</p> <p>Ongoing</p>	<p>JM</p> <p>JM</p> <p>JM/KMc</p>	<p>6/24</p> <p>7/24</p> <p>8/24</p>
--	--	---	---	-----------------------------------	-------------------------------------

		<p>April 2024 update – ICB meetings ongoing. JM meeting with HUTH team to look at internal improvements. May 2024 update – work in HUTH ongoing</p> <p>Work plans To add RDTC SCF to guideline/SCF group to review against local SCFs when published</p> <p>April 2024 update – work ongoing to review SCF workplan. May 2024 update – work ongoing</p> <p>Ratification of guidelines and SCFs To add information around initial supply of devices to erectile dysfunction following prostatectomy guidance April 2024 update: ongoing May 2024: ongoing</p> <p>Ratification of guidelines and SCFs To upload erectile dysfunction following prostatectomy to website and update formulary when uploaded April 2024 update: ongoing May 2024 update: ongoing June 2024 update: ongoing</p> <p>RTDC updates To contact local services to discuss update of pathways and providing feedback to APC in timely manner. JM – to contact joint dermatology services hosted by HUTH (TA916), HUTH rheumatology (TA916/TA918/TA920), joint neurology services hosted by HUTH (TA919) and HUTH gastroenterology (TA925) JM to provide OA with HUTH IBD pathway to discuss with clinical lead. OA to contact NLAG gastroenterology(TA925) with HUTH pathway and NLAG rheumatology (TA916/TA918/TA920) March 2024 update: JM contacted dermatology, rheumatology and awaiting updated guidance, JM contacted neurology and updated guidance on agenda, JM contacted gastroenterology and TA925 already within APC approved pathway. OA contacted NLAG gastroenterology with HUTH guidance agreed to review guidance and aim for next version to be joint guidance. OA contacted NLAG rheumatology April 2024 update: ongoing with with gastro to look at merging guidance. JM met with Prof. Sebastian (IBD lead at HUTH) who is happy to liaise with NLAG as they develop their IBD service.</p> <p>Ratification of guidelines and SCFs: Sacubitril-valsartan</p>	<p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p>	<p>LS/JM</p> <p>JM</p> <p>JM</p> <p>JM</p>	<p>6/24</p> <p>4/24</p> <p>4/24</p> <p>2/24</p> <p>6/24</p>
--	--	--	---	--	---

		<p>JM to contact author around mismatch between monitoring and classification of drug</p> <p>Ratification of guidelines and SCFs: Gonadorelin and Gonadotrophin releasing hormone treatment</p> <p>JM to contact urology team about question about monitoring</p> <p>Traffic Light Status</p> <p>To update formulary (netformulary)</p> <p>Traffic Light Status</p> <p>To update formulary (HERPC)</p> <p>Traffic Light Status</p> <p>To update red list (HERPC)</p> <p>Ratification of joint formulary</p> <p>Update joint formulary with chapter 3</p> <p>Ratification of joint formulary</p> <p>Update joint formulary with chapter 11</p> <p>Ratification of guidelines and SCFs</p> <p>Ocular lubricant guidance – upload onto APC website</p> <p>Ratification of guidelines and SCFs</p> <p>IBD pathway – upload pathway to APC website</p> <p>RDTC updates</p> <p>To update formulary/red list</p> <p>AOB</p> <p>To update template for SCFs</p>	<p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p>		<p>6/24</p> <p>6/24</p> <p>6/24</p> <p>6/24</p> <p>6/24</p> <p>6/24</p> <p>6/24</p> <p>6/24</p> <p>6/24</p> <p>6/24</p> <p>6/24</p>
2024.06.05	Traffic Light Status	<p>Methoxyflurane - Proposed as RED for use in gynaecology outpatients minor procedures to reduce number of minor procedures</p> <p>Morphine hydrochloride trihydrate - Proposed as RED for patient controlled analgesia in post-operative pain management to replace licensed product</p> <p>Uromune- Proposed as RED</p>	To update formulary	JM/LS/AK	7/24
2024.06.06	Feedback from Integrated Medicines Optimisation Committee	<ul style="list-style-type: none"> Guidance on private patients moving to NHS Nice TA approval process Valproate work ongoing 	Noted		
2024.06.07	Work plans	<p>a) Joint formulary alignment</p> <p>b) Shared care frameworks</p> <p>c) Guidelines</p>	Ongoing for information only		
2024.06.08	One System Formulary	<ul style="list-style-type: none"> LA presented information with how one system formulary is proceeding. Covering the three key aspects of governance process alignment for addition of new products or review of existing products, single system formulary which is one formulary across the ICS and 	Noted		

		clinical pathways. No concerns raised by committee; importance of stakeholder engagement raised and ensuring all providers kept within conversations.			
2024.06.09	Ratification of joint formulary	<ul style="list-style-type: none"> Nil this month 			
2024.06.10	Ratification of guidelines and SCFs	<ul style="list-style-type: none"> a) SCF template – updated wording on front page with specialist prescriber and primary care prescriber b) Psoriatic arthritis pathway - Humber dermatology (HUTH and NLAG joint service) pathway updated with TAs. c) Psoriatic pathway – Humber dermatology pathway (HUTH and NLAG joint service) reviewed and updated with TAs. d) Riluzole SCF – SCF reviewed against RDTC version and updated with new formulation and wording. e) Verapamil SCF – SCF reviewed and updated wording around ECGs to match frequency and recommendations in national guidance. Verapamil is within SCF enhanced framework within Hull/ERY but not in NEL/NL f) High output stoma – guidance on medical management of high output stomas. g) Sick day guidance for type 2 diabetes – guidance on management of medicines for patients with type 2 diabetes including dose adjustments for insulin. a) Valproate SCF – the ICS SCF has been updated with new regulatory requirements for valproate 	<ul style="list-style-type: none"> a) Approved b) Approved c) Approved d) Approved e) Approved f) Approved g) Approved with changed title h) Recommended for approval 	JM	
2024.06.11	RDTC updates	<ul style="list-style-type: none"> April 2024 	Update formulary/red list	JM/LS/AK	
2024.06.12	Minutes from subcommittees	<ul style="list-style-type: none"> a) Joint formulary subcommittee (Nil) b) Guideline subcommittee (March 24) 	Attached for info only		
2024.06.13	Additional minutes for information	<ul style="list-style-type: none"> a) HUTH D&TC (Apr 24) b) HFT DTG (Nil) c) NLAG M&T (Nil) d) NYY APC (Apr 24) 	Attached for info only		
2024.06.14	Correspondence received	Nil this month			
2024.06.15	AOB	<ul style="list-style-type: none"> Palliative care clonidine classification raised previously but no action created. Testosterone shared care and menopause service. To add SCF and NY&Y guidance onto next guideline group to review 	<ul style="list-style-type: none"> Palliative care formulary to be added to joint formulary work plan. SCF to be added to agenda and reviewed 	JM JM	7/24 7/24

		<ul style="list-style-type: none"> Progesterone pessaries (Cylogest®) for threatened miscarriage indication; classification changed and informing service missed. 	in next guideline group Add to joint formulary agenda	JM	7/24
2024.06.16	Date of next meeting	3 rd July 2024 13.00 – 15.00 Teams			